Article citationsMore>>

M. J. Berends, Y. Wu, R. H. Sijmons, R. G. Mensink, T. van der Sluis, J. M. Hordijk-Hos, E. G. de Vries, H. Hollema, A. Karrenbeld, C. H. Buys, A. G. van der Zee, R. M. Hofstra and J. H. Kleibeuker, “Molecular and Clinical Characteristics of MSH6 Variants: An Analysis of 25 Index Carriers of a Germline Variant,” American Journal of Human Genetics, Vol. 70, No. 1, 2002, pp. 26-37. doi:10.1086/337944

has been cited by the following article:

• TITLE: Pathological Complete Remission in Young Colon Cancer Patient with a Large Liver Metastasis after FOLFOX-4/Bevacizumab Treatment – A Case Report

  AUTHORS: Elīna Skuja, Arnis Āboliņš, Ilze Priedīte, Gunta Purkalne, Ilze Štrumfa, Jānis Vilmanis, Dagnija Kalniete, Edvīns Miklaševičs, Jānis Gardovskis

  KEYWORDS: Metastatic Colorectal Cancer; Pathological Complete Remission; Bevacizumab

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.3 No.4, July 12, 2012

  ABSTRACT: Introduction. Pathological complete remission of liver metastases is a rare colon cancer treatment outcome with increased 5-year survival of 76%. Case report. Metastatic colorectal cancer patient with pathological complete remission of large hepatic metastasis after palliative chemotherapy in combination with bevacizumab is presented. Solitary liver metastasis measuring 8 cm was observed in computed tomography (CT) scan before combined treatment. The best radiological response during treatment with FOLFOX-4 and bevacizumab therapy was partial remission and patient underwent partial hepatectomy. Since the operation material was free of viable adenocarcinoma cells the effect of FOLFOX-4 in combination with bevacizumab treatment was interpreted as the pathological complete remission. Conclusion. Use of combination chemotherapy and targeted therapy with the aim to reduce initially unresectable liver metastasis is the best option to achieve complete pathological remission and significantly prolong survival.